Biogen Board Approves $5 Billion Stock Buyback -- Update
March 25 2019 - 8:09AM
Dow Jones News
By Colin Kellaher
Biogen Inc. (BIIB) on Monday said its board authorized the
repurchase of up to $5 billion of common stock following last
week's selloff.
The Cambridge, Mass., biopharmaceutical company said the
program, which has no expiration date, is in addition to the
roughly $1.7 billion remaining under a buyback the board approved
in August 2018.
Biogen shares fell 29% Thursday and another 4.5% Friday after
the company and partner Eisai Co. (4523.TO) ended two late-stage
studies of an experimental drug for Alzheimer's disease after
determining it would likely fail to help patients.
Biogen currently has a market capitalization of about $42.6
billion.
Shares of Biogen, which closed Friday at $216.71, edged up 1.6%
in light premarket trading Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 25, 2019 07:54 ET (11:54 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2024 to May 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From May 2023 to May 2024